Inici › Limfoma difús de cèl·lules B grans › Pennsilvània › Philadelphia
Assaigs clínics de Limfoma difús de cèl·lules B grans a Philadelphia, PA
15 estudis de Limfoma difús de cèl·lules B grans busquen participants en centres de Philadelphia i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
ReclutantFase 2
- Fox Chase Cancer Center, Philadelphia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ReclutantEstudi observacional
- Children's Hospital of Philadelphia, Philadelphia
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
ReclutantFase 2
- Thomas Jefferson University Hospital, Philadelphia
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
ReclutantFase 2/3
- Alliance Cancer Specialists (ACS) ( Site 8001), Horsham · a 16 mi
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
ReclutantFase 2
- Abramson Cancer Center and Perelman Center for Advanced Medicine ( Site 0131), Philadelphia
- Temple University Hospital ( Site 0133), Philadelphia
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ReclutantFase 1
- University of Pennsylvania Abramson Cancer Center, Philadelphia
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
ReclutantFase 1/2
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
ReclutantFase 1/2
- Thomas Jefferson University, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
ReclutantFase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
ReclutantFase 1
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutantFase 1
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
ReclutantFase 1
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
ReclutantFase 2
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia
SynKIR-310 for Relapsed/Refractory B-NHL
ReclutantFase 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
ReclutantFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Assaigs de Limfoma difús de cèl·lules B grans en altres ciutats
- New York City, NY21 estudis
- Baldwin Park, CA19 estudis
- Chicago, IL18 estudis
- Houston, TX17 estudis
- Los Angeles, CA17 estudis
- Boston, MA16 estudis
- Milwaukee, WI16 estudis
- Nashville, TN15 estudis
- Portland, OR15 estudis
- Durham, NC14 estudis
- Dallas, TX13 estudis
- Seattle, WA12 estudis
Altres estudis a Philadelphia
- Càncer (tots els tipus)59 estudis
- Càncer de mama56 estudis
- Càncer de pulmó de cèl·lules no petites51 estudis
- Càncer metastàtic46 estudis
- Càncer colorrectal44 estudis
- Càncer d'ovari44 estudis
- Càncer de pròstata44 estudis
- Càncer de pulmó36 estudis
- Leucèmia mieloide aguda34 estudis
- Insuficiència cardíaca31 estudis
- Càncer d'endometri28 estudis
- Depressió26 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.